Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS
Filed with ASX · · 4 pages · English
Avecho Biotechnology Limited on 6ix
In the deck
Story so far
Earlier from Avecho Biotechnology
- Trading Halt
- Appendix 4E - Preliminary Final Report
- Response to ASX Price Query
- December 2024 Quarterly Activities Report & Appendix 4C
- September 2024 Quarterly Activities Report & Appendix 4C
Later from Avecho Biotechnology
- Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
- Avecho receives initial US$3M upfront payment from Sandoz
- March 2025 Quarterly Activities Report & Appendix 4C
- Phase III Trial Update - New Sites Commence Recruitment
- Receipt of R&D Tax Incentive
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology